Product Description: Lusvertikimab (OSE-127) is a humanized IL7R monoclonal antibody. Lusvertikimab is not internalized by target cells and prevents IL7R heterodimerization and subsequent downstream signaling. Lusvertikimab has anti-leukemic efficacy and has the potential for B cell precursor acute lymphoblastic leukemia (BCP-ALL) research[1].
Applications: Cancer-Kinase/protease
Formula: N/A
References: [1]Lennart Lenk, et al. The IL7R-Antagonist OSE-127 Blocks Acute Lymphoblastic Leukemia Development Via a Dual Mode of Action. ACUTE LYMPHOBLASTIC LEUKEMIAS: BIOMARKERS, MOLECULAR MARKERS AND MINIMAL RESIDUAL DISEASE IN DIAGNOSIS AND PROGNOSIS/ NOVEMBER 15, 2022./[2]Elodie Rivière,, et al. Interleukin-7/Interferon Axis Drives T Cell and Salivary Gland Epithelial Cell Interactions in Sjögren's Syndrome. Arthritis Rheumatol. 2021 Apr;73(4):631-640.
CAS Number: 2375835-91-7
Molecular Weight: N/A
Compound Purity: 99.41
Research Area: Cancer
Solubility: H2O
Target: Interleukin Related
English
Deutsch
